Tavo Biotherapeutics, Inc.

Tavo Biotherapeutics, Inc. , based in the US, is focused on developing innovative therapies for glaucoma and retinal diseases, particularly through their advanced pipeline that includes TAV-001, aimed at enhancing ocular health. Tavo Biotherapeutics, Inc. specializes in creating therapies for glaucoma and retinal conditions.

Founded in 2024, the company is headquartered in Laguna Beach, US. The company is led by it's CEO Gary Berman. Tavo Biotherapeutics specializes in the development of innovative therapies targeting glaucoma and retinal diseases. Their flagship product, TAV-001, operates through three primary mechanisms: it reduces intraocular pressure by modulating autonomic signaling, enhances ocular perfusion as a vasodilator, and provides neuroprotection by dampening glutamate release, thus mitigating excitotoxicity and inflammation leading to vision loss.

TAV-001 is in advanced clinical trials, having completed a Phase 1b trial and moving into Phase 2 trials, with a pipeline of therapies aimed at modifying disease progression and preventing vision loss, targeting a global audience of healthcare providers and patients. Tavo Biotherapeutics generates revenue primarily through partnerships and clinical trial funding as they advance their drug development pipeline. The company is expected to collaborate with healthcare providers, hospitals, and research institutions for the distribution and application of their therapies, particularly TAV-001, once commercially available. Their revenue model focuses on direct contracts with healthcare entities involved in therapeutic solutions and clinical studies, with anticipated revenue streams closely tied to the successful commercialization of their products.

In June 2026, Tavo Biotherapeutics, Inc. raised USD 17 million in Series A funding led by Pureos Bioventures, with participation from Polaris Partners and Tau Capital.